hepatitis B News
-
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri, a 3-Antigen Adult Hepatitis B Vaccine
PreHevbri is the only approved 3-antigen hepatitis B vaccine for adults in the United Kingdom Approval follows the European Commission’s marketing authorisation, granted in April 2022 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the UK Medicines and ...
-
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting long-term durability of immune response data following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine has been accepted for oral presentation at The International Liver ...
-
Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2022 Conference being held January 10-13, 2022. The on demand presentation will be available, beginning Monday, January 10, 2022 at 7:00 a.m. E.T. and may ...
-
Dynavax to Present at the Cowen 42nd Annual Health Care Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald Chief Financial Officer, will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, at 2:50 p.m. E.T. The presentation will be webcast ...
-
SpyBiotech featured in The Guardian Value of Vaccines supplement
SpyBiotech has today been featured in The Guardian’s Value of Vaccines supplement, discussing the technological solutions we have developed to accelerate vaccine generation for COVID-19 variants and potentially a range of other diseases for which there are no approved treatments. "The COVID-19 vaccine uses SpyBiotech's unique protein "superglue" technology to display the SARS ...
-
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe. Under the terms of the agreement, specialty vaccine company Valneva will promote ...
-
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. Under the terms of the agreement, $50 million is ...
-
Dynavax to Present at the H.C. Wainwright Global Investment Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022. The on demand presentation will be available, beginning Tuesday, May 24, 2022 at 7:00 a.m. E.T. ...
-
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted restricted stock units (RSUs) covering an aggregate of 16,000 shares of Dynavax common stock as inducements to 2 newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on March 1, 2022, at an exercise price of $12.21 per share, which is equal to the ...
-
Dynavax to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Monday, February 28, 2022 at 4:30 p.m. ...
-
Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald, Chief Financial Officer, will participate in a fireside chat during the William Blair 42nd Annual Growth Stock Conference in Chicago, Illinois on Monday June 6, 2022 at 4:40 ...
-
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer. Mr. Dillman will be responsible for leading VBI’s commercial strategy, sales, and sales operations, including the commercialization of ...
-
Altimmune to Present at Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global Investment Conference Tuesday, May 24, 2022 7:00 am Eastern Time The session will be webcast and can be accessed by visiting the Events section of the Altimmune ...
-
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 94,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 2,500 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company. The stock options ...
-
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 105,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 73,250 shares of Dynavax common stock as inducements to 11 newly-hired employees in connection with commencement of employment with the Company. The stock options ...
-
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study (PROTECT) of the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, were presented in an oral presentation at The ...
-
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in June 2022: Jefferies 2022 Global Healthcare Conference in New York, NY Friday, June 10, 2022 Fireside chat at 10:00 am Eastern Time JMP Securities Life Sciences Conference in New York, NY ...
-
Overview Of SFA Therapeutics
SFA Therapeutics’ CEO Dr Ira Spector presents an overview of the company and its platform technology SFA Overview Presentation on YouTube Introduction to SFA Liver Disease and Oncology Programs. SFA Oncology More information here We received US Patent 10,143,669B2; to prevent Hepatitis B progression to HCC, a liver cancer that affects 400 million patients and causes 1 million cancer ...
-
VBI Vaccines to Participate in the Jefferies Healthcare Conference
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022. Presentation Details Event: Jefferies Healthcare Conference ...
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the results of the Company's recently completed Phase 1 clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH, will be presented in an oral presentation at the 82nd American Diabetes Association (ADA) Scientific ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you